TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID

Hematopoietic Stem Cell Transplantation Clinical Trial

Official title: Phase II/III Study of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated and Haploidentical Donors After TCR Alfa Beta Negative Selection in Pediatric Patients With Primary Immunodeficiency Diseases

Status Completed

Clinical Trial Summary

Treatment Study to assess of safety and efficiency of T cells receptor (TCR) alfa beta depleted graft for hematopoietic stem cell transplantation (HSCT) from haploidentical and unrelated donors in patients with primary immunodeficiency diseases

Clinical Trial Description

Infections, graft versus host diseases (GVHD) and associated morbidity and mortality remains significant problems after unrelated and haploidentical hematopoietic stem sell transplantation (HSCT) in patients with primary immunodeficiency diseases (PID). In this study the hypothesis is that the transplantation of TCR alfa beta depleted peripheral blood stem cells (PBSC) would offers advantages over the use of positively selected CD34+ stem cells in haploidentical HSCT and non-manipulated graft in unrelated HSCT.

The purpose of this study is to evaluate the safety and efficiency of the selective infusion of TCR alfa beta T cell depleted graft in pediatric patients with PID receiving HSCT from haploidentical and unrelated donors. ;

Related Conditions & MeSH terms

• Hematopoietic Stem Cell Transplantation
• Immunologic Deficiency Syndromes
• Primary Immune Deficiency Disorder

• NCT number: NCT02327351
• Study type: Interventional
• Source: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: July 2012
• Completion date: June 2018